论文部分内容阅读
目的:观察康艾注射液对肺癌放疗患者血浆TGF-β_1和ET-1水平的影响。方法:将80例患者随机分为实验组和对照组各40例,实验组采用康艾注射液联合放疗治疗;对照组单纯放疗治疗。观察2组患者治疗前后血浆TGF-β_1和ET-1水平的变化变化情况及放射性肺损伤的发生情况。结果:2组治疗前血浆TGF-β_1、ET-1水平均明显高于健康对照组(P<0.05)。治疗后对照组血浆TGF-β_1、ET-1水平明显高于实验组,2组比较,差异有显著性意义(P<0.05);实验组和对照组放射性肺损伤的发生率分别为17.5%和37.5%,2组比较,差异有显著性意义(P<0.05)。结论:康艾注射液可以明显抑制其放疗过程中血浆TGF-β_1和ET-1水平的升高,降低放射性肺损伤的发生率。
Objective: To observe the effect of Kangai injection on the plasma levels of TGF-β 1 and ET-1 in patients with lung cancer undergoing radiotherapy. Methods: Eighty patients were randomly divided into experimental group and control group, 40 cases each. The experimental group was treated with Kang Ai injection combined with radiotherapy and the control group with radiotherapy alone. The changes of plasma TGF-β 1 and ET-1 levels and the incidence of radiation-induced lung injury in two groups before and after treatment were observed. Results: The levels of plasma TGF-β 1 and ET-1 before treatment in both groups were significantly higher than those in healthy controls (P <0.05). After treatment, the levels of plasma TGF-β 1 and ET-1 in the control group were significantly higher than those in the experimental group (P <0.05). The incidences of radiation-induced lung injury in the experimental and control groups were 17.5% and 37.5%. There was significant difference between the two groups (P <0.05). CONCLUSION: Kangai injection can significantly inhibit the increase of plasma TGF-β 1 and ET-1 levels during radiotherapy and reduce the incidence of radiation-induced lung injury.